These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Peripheral blood stem cells mobilization in patients with relapsed or refractory lymphomas: A single-center experience. Halacoglu A; Serefhanoglu S J Cancer Res Ther; 2024 Apr; 20(3):904-908. PubMed ID: 38102912 [TBL] [Abstract][Full Text] [Related]
32. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926 [TBL] [Abstract][Full Text] [Related]
33. High Proliferating Regulatory T Cells Post-Transplantation Are Associated with Poor Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation. Sumransub N; Cao Q; Wangen R; Brunstein C; Miller JS; Bachanova V Transplant Cell Ther; 2022 Apr; 28(4):184.e1-184.e8. PubMed ID: 35081473 [TBL] [Abstract][Full Text] [Related]
34. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Sobecks RM; Le Beau MM; Anastasi J; Williams SF Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956 [TBL] [Abstract][Full Text] [Related]
35. A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma. Wang L; Wei Q; Shi Q; Guo Z; Qiao Y; Spitz MR Carcinogenesis; 2007 Jul; 28(7):1430-6. PubMed ID: 17341660 [TBL] [Abstract][Full Text] [Related]
36. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30 Grover NS; Hucks G; Riches ML; Ivanova A; Moore DT; Shea TC; Seegars MB; Armistead PM; Kasow KA; Beaven AW; Dittus C; Coghill JM; Jamieson KJ; Vincent BG; Wood WA; Cheng C; Morrison JK; West J; Cavallo T; Dotti G; Serody JS; Savoldo B Lancet Haematol; 2024 May; 11(5):e358-e367. PubMed ID: 38555923 [TBL] [Abstract][Full Text] [Related]
37. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727 [TBL] [Abstract][Full Text] [Related]
38. Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature. Keung YK; Beaty MW; Pettenati M; Levitan D; Hurd DD Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):129-33. PubMed ID: 20371446 [TBL] [Abstract][Full Text] [Related]
39. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Gibson CJ; Lindsley RC; Tchekmedyian V; Mar BG; Shi J; Jaiswal S; Bosworth A; Francisco L; He J; Bansal A; Morgan EA; Lacasce AS; Freedman AS; Fisher DC; Jacobsen E; Armand P; Alyea EP; Koreth J; Ho V; Soiffer RJ; Antin JH; Ritz J; Nikiforow S; Forman SJ; Michor F; Neuberg D; Bhatia R; Bhatia S; Ebert BL J Clin Oncol; 2017 May; 35(14):1598-1605. PubMed ID: 28068180 [TBL] [Abstract][Full Text] [Related]
40. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]